… Asian patients with a known end date (the remaining 3 E/SE Asian patients and 29 non-E/SE
Asian patients … up [E/SE Asian patients n = 3, 100%; non-E/SE Asian patients n = 19, 66%]). …

… -kinase inhibitor erlotinib as maintenance treatment in NSCLC patients without progression
… We report a retrospective subanalysis of Asian patients enrolled in SATURN. Patients with …

… Our results show that both gefitinib and erlotinib are effective for treating advanced
NSCLC in East Asian patients, with comparable PFS, OS, ORR, and DCR. Erlotinib induces a …

… safety profile. However, little is known about the efficacy and … of erlotinib as first-line treatment,
especially for elderly patients … of erlotinib as first-line treatment in Asian elderly patients …

… EGFR mutations occur more frequently in Asian patients compared with Caucasian patients
(… safety The safety population included 110 patients for the erlotinib arm and 104 for the GP …

… patients who … patients in this study received erlotinib as a fourth-line or subsequent treatment,
the results from this study were similar to those of clinical studies. We deduce that erlotinib …

… compared the efficacy and safety of gefitinib and erlotinib in Chinese patients with EGFRm+
… indicated similar efficacy of erlotinib in European patients as in Asian patients, with median …

… erlotinib; … Asian patients compared with Caucasian patients, this exploratory analysis
assessed the possible association of ethnicity (EA and non-EA populations) with efficacy and safety …

… The results of Asian patients and other ethnicities are similar (HR, 0.6 and 0.8, respectively).
The most important group is of male smokers with epidermoid carcinoma. In this population, …

… The aim of this study was to evaluate the efficacy and safety of Erlotinib in Japanese
patients with previously treated non-small cell lung cancer (NSCLC). Available tumor biopsy …